Marshall Wace North America’s Adaptive Biotechnologies ADPT Stock Holding History

Marshall Wace North America’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,498	Closed	-$225K	–	1394
2021 Q2	$225K	Sell	5,498 -26,698	-83%	-$1.04M	﹤0.01%	1329
2021 Q1	$1.3M	Sell	32,196 -207,987	-87%	-$11.3M	0.01%	952
2020 Q4	$14.2M	Buy	240,183 +77,139	+47%	+$3.98M	0.06%	312
2020 Q3	$7.93M	Buy	+163,044	New	+$6.85M	0.05%	317
2020 Q2	–	Sell	-97,230	Closed	-$2.7M	–	1127
2020 Q1	$2.7M	Buy	97,230 +95,711	+6,301%	+$2.67M	0.02%	428
2019 Q4	$46K	Sell	1,519 -61,311	-98%	-$1.76M	﹤0.01%	1159
2019 Q3	$1.94M	Sell	62,830 -136,670	-69%	-$5.58M	0.01%	551
2019 Q2	$9.64M	Buy	+199,500	New	+$8.84M	0.06%	246

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Marshall Wace North America's ADPT Position: Q3 2021 in Review

Marshall Wace North America sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 5,498 shares — an estimated $225K sold.

Marshall Wace North America first reported a position in ADPT in Q2 2019 and held it in 8 quarters. The position peaked at $14.2M in Q4 2020. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

Marshall Wace North America reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 5,498 Adaptive Biotechnologies shares in Q3 2021, an estimated $225K.
Marshall Wace North America first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 8 quarters.
Marshall Wace North America's Adaptive Biotechnologies position peaked at $14.2M in Q4 2020.
219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.